Signaling Scaffolds for Specificity in Neuromodulator Action
神经调节剂作用特异性的信号支架
基本信息
- 批准号:10350625
- 负责人:
- 金额:$ 36.22万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-03-01 至 2024-02-28
- 项目状态:已结题
- 来源:
- 关键词:A kinase anchoring proteinAMPA ReceptorsAdrenergic AgentsAdrenergic ReceptorAlzheimer&aposs DiseaseArousalAttentionBehavioralBindingBiologicalC-terminalCardiovascular DiseasesCardiovascular systemCell modelCellsChemosensitizationClinicalComplexCoupledCyclic AMP-Dependent Protein KinasesDLG1 geneDendritesDisinhibitionDrug TargetingElectrophysiology (science)EmotionalEndocytosisEventExcisionExhibitsG-Protein-Coupled ReceptorsGene TransferGlutamatesHippocampus (Brain)Immune System DiseasesImmunologicsImpairmentIndividualIntracellular Signaling ProteinsIon ChannelKnock-outLeadLearningLigand BindingLigandsLinkMediatingMemoryMental disordersModelingMolecularMultiprotein ComplexesMusNerve DegenerationNeurologicNeuromodulatorNeuronsNorepinephrineOrganOutcomeParkinson DiseasePenetrancePeptidesPharmaceutical PreparationsPharmacologic SubstancePharmacologyPhosphorylationPostsynaptic MembraneProcessPropertyProtein FamilyProtein IsoformsProteinsPsychiatric therapeutic procedurePublishingRNA InterferenceRegulationSchemeSignal PathwaySignal TransductionSignal Transduction PathwaySiteSpecific qualifier valueSpecificitySurfaceSynapsesSynaptic TransmissionSynaptic plasticityTherapeuticTimeViralVoltage-Gated Potassium ChannelWorkadenylatebasebeta-2 Adrenergic Receptorsclassical conditioningclinical applicationcognitive enhancementcognitive functionexperimental studyheuristicshippocampal pyramidal neuronimprovedinsightloss of functionmembrane-associated guanylate kinasemutantnervous system disorderneural circuitnovelparalogous genepostsynapticpreventreceptorreconstitutionrecruitscaffoldsegregationsynaptic function
项目摘要
Abstract
b2-adrenoceptor signaling is critical for adrenergic regulation of synaptic plasticity and neurodegeneration, and
has been proposed to have therapeutic potentials for Alzheimer’s and Parkinson’s diseases. However, b-
adrenoceptors (b-ARs) exhibit highly complicated pharmaceutical effects. This is exemplified by clinical results,
in which b-AR drugs modulate receptor paralogs in different organs to elicit both therapeutic and clinically
harmful effects at the same time. We aim to understand the signaling specificity of b2-adrenoceptors (b2-ARs),
mechanisms through which they are selectively coupled to different intracellular signaling proteins and
molecular effectors under different conditions. Our published and preliminary results manifest the signaling
scaffold, synapse-associated protein of 97 kDa (SAP97) as an orchestrator of b2-AR signaling in hippocampal
neurons. Specifically, the b-isoform of SAP97 (S97b) tethers b2-ARs and the effector voltage-gated potassium
channel subunit Kv1.1 together to transduce activation of b2-AR signaling into inhibition of Kv1.1 and its removal
from the dendrite surface (collectively referred to as Kv1.1 inhibition). Consequently, b2-AR-induced Kv1.1
inhibition increases dendritic excitability and lowers the induction threshold for long-term synaptic potentiation.
Given b2-AR-signaling also regulates the phosphorylation of the AMPA receptor subunit GluA1, but through a
different signaling scaffold, we hypothesize that signaling scaffolds mediate the signaling specificity and the
interactions can be used as specific pharmacological targets. In this proposal, using the S97b/b2-AR/Kv1.1
complex as an exemplary model, we aim to gain mechanistic insights into a) how the diverse b2-AR signaling
events are specifically regulated; b), what the molecular components of the S97b/b2-AR/Kv1.1 complex are to
achieve signaling specificity; and c) what are the behavioral correlates of the S97b/b2-AR/Kv1.1 signaling pathway
in mice. Importantly, in SAP97-lacking neurons, the signaling pathway governing b2-AR dependent dendritic
excitability is impaired with a ~100% penetrance, allowing an analysis with minimal confounding effects of
functional redundancy. The outcomes of our proposed experiments will provide a set of mechanistically clear
drug targets for treating psychiatric, neurological, immunological or cardiovascular disorders, and perhaps more
importantly lead to a novel and generalizable molecular scheme, through which G-protein-coupled receptors
achieve biased and selective regulations of specific effector proteins to modulate synaptic transmission and
plasticity.
抽象的
b2-肾上腺素受体信号传导对于突触可塑性和神经变性的肾上腺素能调节至关重要,
已被认为具有治疗阿尔茨海默病和帕金森病的潜力。
肾上腺素受体(b-AR)表现出高度复杂的药物作用,临床结果证明了这一点。
其中 b-AR 药物调节不同器官中的受体旁系同源物,以引起治疗和临床效果
我们的目标是了解 b2-肾上腺素受体 (b2-AR) 的信号传导特异性,
它们选择性地与不同的细胞内信号蛋白偶联的机制
我们发表的初步结果表明了不同条件下的分子效应。
支架,97 kDa 的突触相关蛋白 (SAP97) 作为海马 b2-AR 信号传导的协调者
具体来说,SAP97 (S97b) 的 b-异构体连接 b2-AR 和效应电压门控钾。
通道亚基 Kv1.1 一起将 b2-AR 信号传导的激活转导为 Kv1.1 的抑制及其去除
从树突表面(统称为 Kv1.1 抑制)检查,b2-AR 诱导 Kv1.1。
抑制增加树突的兴奋性并降低长期突触增强的诱导阈值。
b2-AR 信号传导还调节 AMPA 受体亚基 GluA1 的磷酸化,但通过
不同的信号支架,我们认为信号支架介导信号特异性和
在本提案中,使用 S97b/b2-AR/Kv1.1 可以用作特定的药理学靶点。
作为一个示例性模型,我们的目标是获得以下机制的见解:a) 多样化的 b2-AR 信号传导如何
b) S97b/b2-AR/Kv1.1 复合物的分子成分有何作用?
实现信号特异性;c) S97b/b2-AR/Kv1.1 信号通路的行为相关性是什么
重要的是,在 SAP97 系带神经元中,控制 b2-AR 依赖性树突的信号通路。
兴奋性受到约 100% 外显率的影响,允许以最小的混杂效应进行分析
我们提出的实验结果将提供一组机械上清晰的结果。
用于治疗精神、神经、免疫或心血管疾病等疾病的药物靶标
重要的是导致了一种新颖且可推广的分子方案,通过该方案G蛋白偶联受体
实现对特定效应蛋白的有偏性和选择性调节,以调节突触传递和
可塑性。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Oliver Schlueter其他文献
Oliver Schlueter的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Oliver Schlueter', 18)}}的其他基金
Signaling Scaffolds for Specificity in Neuromodulator Action
神经调节剂作用特异性的信号支架
- 批准号:
10582659 - 财政年份:2019
- 资助金额:
$ 36.22万 - 项目类别:
相似国自然基金
翻译水平选择性调控皮层AMPA受体表达促进神经元形态功能发育及神经环路塑造的分子机制及生理功能研究
- 批准号:32360194
- 批准年份:2023
- 资助金额:31 万元
- 项目类别:地区科学基金项目
AMPA受体正向变构调节剂快速抗抑郁作用及其神经机制研究
- 批准号:82371524
- 批准年份:2023
- 资助金额:47 万元
- 项目类别:面上项目
基于奖赏环路内AMPA受体相关的突触可塑性变化探讨痫蛋白在抑郁症发病中的作用及机制
- 批准号:82360277
- 批准年份:2023
- 资助金额:32.2 万元
- 项目类别:地区科学基金项目
ABHD6与AMPA受体结合位点的鉴定及该位点在AMPA受体转运和功能调控中的作用研究
- 批准号:32300794
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
SNX32棕榈酰化修饰调控AMPA受体介导的突触可塑性在AD中的作用机制
- 批准号:32360219
- 批准年份:2023
- 资助金额:35 万元
- 项目类别:地区科学基金项目
相似海外基金
Signaling Scaffolds for Specificity in Neuromodulator Action
神经调节剂作用特异性的信号支架
- 批准号:
10582659 - 财政年份:2019
- 资助金额:
$ 36.22万 - 项目类别:
PKA targeting: A novel mechanism for GPCR resensitization
PKA 靶向:GPCR 再敏化的新机制
- 批准号:
8212500 - 财政年份:2008
- 资助金额:
$ 36.22万 - 项目类别:
PKA targeting: A novel mechanism for GPCR resensitization
PKA 靶向:GPCR 再敏化的新机制
- 批准号:
7751934 - 财政年份:2008
- 资助金额:
$ 36.22万 - 项目类别:
PKA targeting: A novel mechanism for GPCR resensitization
PKA 靶向:GPCR 再敏化的新机制
- 批准号:
7580680 - 财政年份:2008
- 资助金额:
$ 36.22万 - 项目类别:
Regulation of AKAP79 Postsynaptic Membrane Targeting
AKAP79 突触后膜靶向的调节
- 批准号:
7472488 - 财政年份:2001
- 资助金额:
$ 36.22万 - 项目类别: